If you work in drug development, chemical safety, or regulatory science, you have probably noticed something shifting. New acronyms appear at conferences. Regulatory conversations sound different. Research roadmaps increasingly point to one idea: New Approach Methodologies (NAMs).
NAMs did not emerge just because science needed another buzzword. They emerged because the traditional safety testing system has reached a turning point. For decades, chemical and drug safety assessments have relied heavily on animal studies. While this approach has contributed to human health protection, society is increasingly questioning the sustainability, efficiency, ethical implications, and human relevance of an animal-centric testing paradigm (1).
The result is not rebellion against past science but evolution. That evolution is where NAMs enter the story.
Traditional toxicology often depends on observing adverse effects in experimental animals exposed to high doses of substances. Translating these findings to realistic human exposure scenarios introduces unavoidable uncertainty due to differences in metabolism, exposure conditions, and biological pathways (1).
At the same time, regulators face challenges related to scale. Thousands of chemicals exist globally, many of which lack sufficient datasets for robust safety assessment. Completing traditional testing requirements solely through animal studies could take decades and require substantial resources (1).
So, What Exactly Are NAMs?
NAMs are defined as in vitro, in chemico, or computational methods that improve chemical safety assessment while reducing reliance on animal testing (2).
Approaches under NAMs include human cell and tissue models, high-throughput bioassays, omics technologies, and microphysiological systems (1). These tools enable scientists to investigate mechanisms of toxicity instead of simply observing outcomes.
NAMs Are Tools; the Real Shift Is NGRA
NAMs support the broader transformation toward Next Generation Risk Assessment (NGRA), an exposure-led, hypothesis-driven framework that integrates computational, chemical, and biological data to evaluate safety using biologically relevant evidence (2).
NGRA focuses on protecting exposed populations under realistic conditions rather than predicting effects observed only at unrealistically high exposures.
Scientific advancements now allow researchers to mimic human biology and gain mechanistic insights into toxicity pathways (3). Regulatory agencies in the United States, Canada, and the European Union increasingly incorporate NAMs into decision-making where scientifically appropriate (3). For industry, the time and resources required for conventional animal testing often do not align with modern innovation timelines, further driving adoption of NAMs (1).
Challenges Still Ahead
Despite clear advantages, barriers remain, including challenges with scientific validation, regulatory familiarity, legislative adaptation, and cultural inertia around established methods (2).
Issues related to predictivity, reproducibility, and regulatory integration continue to be addressed (1).
The rise of NAMs reflects a gradual transition toward relevant, human mechanism-informed safety science. Regulatory agencies worldwide are investing in collaborative frameworks and validation programs to ensure NAM-generated data support protective decisions for human health and the environment (3).
What’s Next
Science is changing. The tools are ready. But one critical question remains.
Is the global regulatory system ready to evolve alongside them?
In our next blog, we step beyond the science of NAMs and explore the forces quietly reshaping how safety decisions will be made worldwide in the near future. Stay tuned, because the next chapter may challenge how we think about drug testing altogether.
At Gelomics, we are exploring how advanced 3D cellular models can help bridge the gap between biological complexity and predictive toxicology.
Advancing drug discovery and toxicology research requires in vitro models that deliver both physiological relevance and reproducibility. At Gelomics, we are focused on developing advanced 3D cellular systems that help teams generate more reliable data and streamline the path from discovery to application.
Discover how the LunaX™ Mechanistic 3D Tissue Culture Platform and our scalable 3D cell culture technologies are designed to support consistent, high-quality results for research teams and industry partners.
1. Schmeisser S. et al. (2023). New approach methodologies in human regulatory toxicology Not if but how and when. Environment International.
2. Sewell F. et al. (2024). New approach methodologies identifying and overcoming hurdles to accelerated adoption. Toxicology Research.
3. Stucki A.O. et al. (2022). Use of new approach methodologies to meet regulatory requirements for the assessment of industrial chemicals and pesticides for effects on human health. Frontiers in Toxicology.